Xencor Inc (XNCR)

Sentiment-Signal

18,6
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
3.8
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Stammdaten

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Unternehmen & Branche

NameXencor Inc
TickerXNCR
CIK0001326732
BoerseUS
SektorHealthcare
IndustrieBiotechnology
SIC2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP98401f105
ISINUS98401F1057
TypCommon Stock
Marktkapitalisierung940,9 Mio. USD
Beta0,99
Dividendenrendite0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

PeriodeFilingUmsatzNettoergebnisEPSAktivaEigenkapital
2025-12-3110-K125,576,000-91,923,000-1.24875,495,000635,587,000
2025-09-3010-Q20,999,000-6,027,000-0.08868,811,000625,316,000
2025-06-3010-Q43,608,000-30,825,000-0.41879,424,000620,351,000
2025-03-3110-Q32,732,000-48,418,000-0.66904,689,000639,874,000
2024-12-3110-K110,493,000-232,618,000-3.58951,945,000677,611,000
2024-09-3010-Q17,796,000-46,288,000-0.72983,635,000723,836,000
2024-06-3010-Q23,907,000-67,337,000-1.09826,167,000564,325,000
2024-03-3110-Q15,997,000-73,440,000-1.20884,255,000612,526,000
2023-12-3110-K174,615,000-133,133,000-2.20965,135,000661,750,000
2023-09-3010-Q59,164,000-24,269,000-0.40778,430,000669,010,000
2023-06-3010-Q45,523,000-21,954,000-0.37778,121,000678,876,000
2023-03-3110-Q18,962,000-60,763,000-1.02803,411,000683,583,000
2022-12-3110-K164,579,000-55,181,000-0.93846,266,000727,496,000
2022-09-3010-Q27,299,000-32,759,000-0.55835,269,000722,698,000
2022-06-3010-Q30,175,000-33,975,000-0.57851,325,000742,341,000
2022-03-3110-Q85,495,00023,594,0000.39857,922,000763,023,000
2021-12-3110-K275,111,00082,631,0001.37838,211,000733,504,000
2021-09-3010-Q19,683,000-40,191,000-0.69697,264,000618,860,000
2021-06-3010-Q67,447,00052,248,0000.87695,602,000646,938,000
2021-03-3110-Q33,965,000-2,487,000-0.04692,737,000583,612,000

Fondsaktivität (Vorquartalsvergleich)

FondsAktuell (Stk)Vorquartal (Stk)Veränderung (Stk)Wert (USD)StatusΔTrend
BlackRock, Inc.11,927,218011,927,218182,605,708Neu+100,0%
PRIMECAP MANAGEMENT CO/CA/10,218,322010,218,322156,442,509Neu+100,0%
VANGUARD GROUP INC7,165,45007,165,450109,703,040Neu+100,0%
RTW INVESTMENTS, LP6,777,46106,777,461103,762,928Neu+100,0%
STATE STREET CORP4,507,25404,507,25469,006,059Neu+100,0%
GEODE CAPITAL MANAGEMENT, LLC1,752,91801,752,91826,842,201Neu+100,0%
MORGAN STANLEY1,508,72701,508,72723,098,626Neu+100,0%
Legal & General Group Plc1,308,08801,308,08820,026,828Neu+100,0%
DIMENSIONAL FUND ADVISORS LP1,249,28801,249,28819,125,117Neu+100,0%
BAKER BROS. ADVISORS LP1,102,10601,102,10616,873,243Neu+100,0%
GOLDMAN SACHS GROUP INC753,2580753,25811,532,380Neu+100,0%
JOHNSON & JOHNSON748,0620748,06211,452,829Neu+100,0%
Jefferies Financial Group Inc.720,4400720,44011,029,936Neu+100,0%
Lynx1 Capital Management LP705,5580705,55810,802,093Neu+100,0%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC700,4350700,43510,723,660Neu+100,0%
NORTHERN TRUST CORP674,6570674,65710,328,998Neu+100,0%
UBS Group AG638,0210638,0219,768,101Neu+100,0%
BANK OF AMERICA CORP /DE/629,4080629,4089,636,237Neu+100,0%
MILLENNIUM MANAGEMENT LLC594,4350594,4359,100,800Neu+100,0%
PANAGORA ASSET MANAGEMENT INC583,7780583,7788,937,641Neu+100,0%
TORONTO DOMINION BANK491,0000491,0007,517,210Neu+100,0%
Hudson Bay Capital Management LP425,0000425,0006,506,750Neu+100,0%
BARCLAYS PLC359,2350359,2355,499,890Neu+100,0%
PRINCIPAL FINANCIAL GROUP INC340,3260340,3265,210,391Neu+100,0%
CITADEL ADVISORS LLC321,8080321,8084,926,881Neu+100,0%
JPMORGAN CHASE & CO303,9790303,9794,653,918Neu+100,0%
TWO SIGMA INVESTMENTS, LP268,7370268,7374,114,363Neu+100,0%
Invesco Ltd.265,8200265,8204,069,705Neu+100,0%
JACOBS LEVY EQUITY MANAGEMENT, INC259,3190259,3193,970,174Neu+100,0%
PUBLIC SECTOR PENSION INVESTMENT BOARD247,2420247,2423,785,275Neu+100,0%
DEUTSCHE BANK AG\216,5680216,5683,315,656Neu+100,0%
Susquehanna Portfolio Strategies, LLC191,4630191,4632,931,299Neu+100,0%
Trexquant Investment LP175,1520175,1522,681,577Neu+100,0%
AMERICAN CENTURY COMPANIES INC174,6030174,6032,673,172Neu+100,0%
RHUMBLINE ADVISERS165,7970165,7972,538,330Neu+100,0%
Nantahala Capital Management, LLC164,6390164,6392,520,623Neu+100,0%
AMERIPRISE FINANCIAL INC135,8060135,8062,079,190Neu+100,0%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC119,7890119,7891,833,969Neu+100,0%
Swiss National Bank119,6000119,6001,831,076Neu+100,0%
CITIGROUP INC112,2750112,2751,718,930Neu+100,0%
AQR CAPITAL MANAGEMENT LLC112,2710112,2711,718,869Neu+100,0%
Essex LLC98,661098,6611,510,500Neu+100,0%
FMR LLC92,883092,8831,422,047Neu+100,0%
WINTON GROUP Ltd88,038088,0381,347,862Neu+100,0%
VOLORIDGE INVESTMENT MANAGEMENT, LLC87,717087,7171,342,947Neu+100,0%
MANUFACTURERS LIFE INSURANCE COMPANY, THE82,942082,9421,252,541Neu+100,0%
WELLS FARGO & COMPANY/MN79,667079,6671,219,702Neu+100,0%
ALLIANCEBERNSTEIN L.P.72,090072,0901,103,698Neu+100,0%
INTECH INVESTMENT MANAGEMENT LLC70,612070,6121,081,070Neu+100,0%
PRUDENTIAL FINANCIAL INC67,570067,5701,034,497Neu+100,0%

Insider-Transaktionen (12 Monate)

DatumInsiderRolleTypStückzahlKursWert (USD)ΔTrend
2026-04-10Cornelissen Bart JanOfficer, SR. VICE PRESIDENT & CFOOpen Market Sale-3,49912.29-42,990.46-20,0%
2026-03-06Desjarlais John ROfficer, SR. VICE PRESIDENT & CSOOpen Market Sale-2,50211.02-27,571.29-12,8%
2026-03-06Eckert CeliaOfficer, SVP, GENERAL COUNSELOpen Market Sale-1,76711.02-19,471.81-9,1%
2026-03-06Dahiyat Bassil IDirector, Officer, PRESIDENT & CEOOpen Market Sale-6,60611.02-72,796.14-33,8%
2026-03-05Cornelissen Bart JanOfficer, SR. VICE PRESIDENT & CFOOpen Market Sale-2,51711.25-28,304.92-13,2%
2026-03-05Desjarlais John ROfficer, SR. VICE PRESIDENT & CSOOpen Market Sale-4,11811.25-46,308.97-21,5%
2026-03-05Dahiyat Bassil IDirector, Officer, PRESIDENT & CEOOpen Market Sale-14,87011.25-167,220.59-77,7%
2026-03-05Eckert CeliaOfficer, SVP, GENERAL COUNSELOpen Market Sale-3,24411.25-36,480.40-17,0%
2026-03-03Dahiyat Bassil IDirector, Officer, PRESIDENT & CEOOpen Market Sale-6,75811.90-80,387.09-37,4%
2026-03-03Desjarlais John ROfficer, SR. VICE PRESIDENT & CSOOpen Market Sale-2,66311.90-31,676.65-14,7%
2026-03-03Eckert CeliaOfficer, SVP, GENERAL COUNSELOpen Market Sale-1,49211.90-17,747.49-8,3%
2025-12-19Dahiyat Bassil IDirector, Officer, PRESIDENT & CEOOpen Market Sale-114,37715.71-1,796,862.67-835,4%
2025-12-19Desjarlais John ROfficer, SR. VICE PRESIDENT & CSOOpen Market Sale-73,36715.72-1,153,329.24-536,2%
2025-06-16GUSTAFSON KURT ADirectorOpen Market Sale-2,9939.22-27,595.46-12,8%
2025-06-16GORMAN KEVIN CHARLESDirectorOpen Market Sale-3,1739.22-29,255.06-13,6%
2025-06-16Feigal EllenDirectorOpen Market Sale-2,9939.22-27,595.46-12,8%
2025-05-02Valente NancyOfficer, EVP, Chief Development OfficerOpen Market Sale-4,61611.03-50,914.48-23,7%

Top-Fondshalter

Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.

FondsAnteileWert (USD)Anteil (%)
BlackRock, Inc.11,927,218182,605,70819.43
PRIMECAP MANAGEMENT CO/CA/10,218,322156,442,50916.64
VANGUARD GROUP INC7,165,450109,703,04011.67
RTW INVESTMENTS, LP6,777,461103,762,92811.04
STATE STREET CORP4,507,25469,006,0597.34
GEODE CAPITAL MANAGEMENT, LLC1,752,91826,842,2012.86
MORGAN STANLEY1,508,72723,098,6262.46
Legal & General Group Plc1,308,08820,026,8282.13
DIMENSIONAL FUND ADVISORS LP1,249,28819,125,1172.03
BAKER BROS. ADVISORS LP1,102,10616,873,2431.80
GOLDMAN SACHS GROUP INC753,25811,532,3801.23
JOHNSON & JOHNSON748,06211,452,8291.22
Jefferies Financial Group Inc.720,44011,029,9361.17
Lynx1 Capital Management LP705,55810,802,0931.15
CHARLES SCHWAB INVESTMENT MANAGEMENT INC700,43510,723,6601.14
NORTHERN TRUST CORP674,65710,328,9981.10
UBS Group AG638,0219,768,1011.04
BANK OF AMERICA CORP /DE/629,4089,636,2371.03
MILLENNIUM MANAGEMENT LLC594,4359,100,8000.97
PANAGORA ASSET MANAGEMENT INC583,7788,937,6410.95

Hinweis

Erweitert ×